Oseltamivir Dosing for Influenza Infection in Premature Neonates | Zendy

Edward P. Acosta | Zendy; Penelope Jester | Zendy; Péter Gál | Zendy; John Wimmer | Zendy; Joni Wade | Zendy; Richard J. Whitley | Zendy; David W. Kimberlin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oseltamivir Dosing for Influenza Infection in Premature Neonates

Author(s) -

Edward P. Acosta,

Penelope Jester,

Péter Gál,

John Wimmer,

Joni Wade,

Richard J. Whitley,

David W. Kimberlin

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/654930

Subject(s) - oseltamivir , dosing , medicine , neonatal intensive care unit , population , intensive care unit , neuraminidase inhibitor , pediatrics , emergency medicine , intensive care medicine , pharmacology , covid-19 , environmental health , disease , infectious disease (medical specialty)

Under the Emergency Use Authorization issued in April 2009, oseltamivir can be used to treat 2009 influenza A (H1N1) virus infection in children aged <1 year. No data exist on the dosing of oseltamivir in premature babies. A hospital health care worker inadvertently exposed 32 neonatal intensive care unit babies to 2009 influenza A (H1N1); a protocol was expeditiously implemented to collect samples for pharmacokinetics and dosage evaluation. Results suggest 1.0 mg/kg/dose twice daily in premature babies produces oseltamivir carboxylate exposures similar to that in older children receiving 3.0 mg/kg/dose twice daily. These results provide initial guidance on dosing oseltamivir in this vulnerable population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research